Anthrax

Fast-tracked anthrax drug, Anthim, advances into human clinical trials

Published in Anti-Infectives Week, October 31st, 2005

Elusys Therapeutics, Inc., a privately held biopharmaceutical company focused on the development of targeted anti-infective therapeutics, announced that it has received Institutional Review board (IRB) approval for a phase I human safety study of Anthim, the company's anthrax antibody therapeutic.

Anthim has been granted "fast track" status (May 6, 2005) by the U.S. Food & Drug Administration (FDA) and this study will begin in the coming weeks.

The company also reported that it has initiated manufacturing scale-up to produce Anthim in commercial quantities in the event of U.S. government purchase for the Strategic National Stockpile.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Anti-Infectives Week

Source: Anti-Infectives Week (2005-10-31)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry